0001193125-21-091154.txt : 20210323 0001193125-21-091154.hdr.sgml : 20210323 20210323160258 ACCESSION NUMBER: 0001193125-21-091154 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210321 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20210323 DATE AS OF CHANGE: 20210323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Foghorn Therapeutics Inc. CENTRAL INDEX KEY: 0001822462 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39634 FILM NUMBER: 21764802 BUSINESS ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-586-3100 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 d139127d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 21, 2021

 

 

Foghorn Therapeutics Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39634   47-5271393

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

500 Technology Square, Ste 700

Cambridge, MA

   02139
(Address of principal executive offices)   (Zip Code)

(Registrant’s telephone number, including area code): (617) 245-0399

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   FHTX   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.02

Results of Operations and Financial Condition.

On March 21, 2021, José Baselga M.D. Ph.D., a member of our board of directors, science committee and nominating and corporate governance committee, passed away. We are deeply grateful for the years of service on our board of directors and its committees. Our deepest sympathies are with Dr. Baselga’s family and friends.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  FOGHORN THERAPEUTICS INC.
By:  

/s/ Adrian Gottschalk

  Adrian Gottschalk,
  Chief Executive Officer

Date: March 23, 2021